This is because the incretin properties of analogues of GLP‐1, one signal within this complex regulatory system, are already being used clinically to treat type II diabetes, and similar pharmaceutical products are now being approved more widely for use to achieve body mass reductions (Vigil et al., 2022), increasingly in females of reproductive age. Here, GCG is linked to type 2 diabetes mellitus.